CN114432337B - Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases - Google Patents
Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases Download PDFInfo
- Publication number
- CN114432337B CN114432337B CN202210231757.6A CN202210231757A CN114432337B CN 114432337 B CN114432337 B CN 114432337B CN 202210231757 A CN202210231757 A CN 202210231757A CN 114432337 B CN114432337 B CN 114432337B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- fruiting body
- fat
- group
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
Abstract
The invention discloses an application of cordyceps guangdongensis fruiting body polysaccharide in preparing a medicine for treating and improving obesity and related diseases. The invention provides application of cordyceps guangdongensis fruiting body polysaccharide in preparation of a medicine for treating and improving obesity and related diseases. The cordyceps guangdongensis fruiting body polysaccharide plays a positive role in relieving obesity, reducing blood fat and protecting liver, shows good development and application prospects, and greatly expands the application field of cordyceps guangdongensis fruiting body polysaccharide.
Description
The technical field is as follows:
the invention belongs to the field of biological medicines and health care products, and particularly relates to application of cordyceps guangdongensis fruiting body polysaccharide in preparation of a medicine for treating and improving obesity and related diseases.
Background art:
with the improvement of living standard of people, fat accumulation in a body is caused due to excessive intake of nutrient substances, and further obesity and related metabolic chronic metabolic disorder diseases are caused. At present, obesity becomes a common and serious public health problem, not only can cause the difference of body states, but also more seriously, chronic metabolic syndrome caused by the obesity, such as hyperglycemia, hyperlipidemia, hypertension, type II diabetes, fatty liver, coronary heart disease, colon cancer, alzheimer disease and other diseases, and becomes an important invisible killer for restricting the body health of people. Hyperlipidemia is a major complication of obesity, a systemic disease characterized by high levels of Triglycerides (TG), total Cholesterol (TC) and Low Density Lipoprotein Cholesterol (LDLC). In obese subjects, excess triglycerides can significantly induce macrophage accumulation in visceral adipose tissue, further release proinflammatory cytokines and adipokines (e.g., TNF-and IL-6), and further cause metabolic abnormalities. In addition, obesity causes non-alcoholic fatty liver, causing accumulation of lipids in the liver. Therefore, effective prevention and treatment of obesity and metabolic disorders thereof is a hot issue, and has attracted attention and research of scholars all over the world.
The edible and medicinal fungus polysaccharide has good effects on relieving the weight and the fat tissue weight of obese mice, reducing blood lipid parameters in serum and the like, for example, ganoderma lucidum polysaccharide, cordyceps militaris polysaccharide, hericium erinaceus polysaccharide and the like can improve the weight and the blood lipid parameters of the obese mice and relieve obesity and related chronic metabolic disease symptoms such as lipid metabolic disorder in the mice by regulating the expression of intestinal flora and glycolipid metabolism related genes. Cordyceps guangdongensis (Tolypocladium guangdongensis = Cordycepsguangdongensis) is a kind of edible and medicinal fungi which is peculiar to China and safe for eating and medicinal purposes, belongs to a family different from Cordyceps militaris (C.militaris) and belongs to the same family but a different genus from Cordyceps sinensis (Ophiocerdyceps sinensis), and is obtained in 2013 as a new resource food of the Ministry of health, and is rich in nutritional active ingredients such as polysaccharide, crude protein, trace elements and the like. In vitro cell and mouse in vivo experiments show that: the Cordyceps guangdongensis polysaccharide has strong antioxidant capacity, ferrous ion chelating capacity and reducing capacity; meanwhile, the cordyceps guangdongensis polysaccharide obviously promotes the generation of B cells of mouse antibody-producing cells, improves the level and the volume number of the mouse antibody, and further enhances the humoral immunity function of the mouse. However, the research on the efficacy of cordyceps guangdongensis fruiting body polysaccharide in relieving obesity, reducing blood fat and other related metabolic diseases is not reported at present. Therefore, the research on the effects of relieving weight gain, reducing blood fat, improving related metabolic symptoms and the like of the cordyceps guangdongensis sporocarp polysaccharide and the research and development of products of the cordyceps guangdongensis sporocarp polysaccharide have good social benefit and economic value.
The invention content is as follows:
the invention aims to provide application of cordyceps guangdongensis sporocarp polysaccharide in preparation of medicines for treating and improving obesity and related diseases, and provides a new raw material for researching and developing products related to obesity and metabolic disorder diseases in the fields of biomedicine, health-care products and the like.
Experiments show that the intervention of cordyceps guangdongensis sporocarp polysaccharide can obviously reduce the weight, increase the weight gain rate, the Lee's index, the epididymal fat and inguinal fat coefficient, the triglyceride content, the total cholesterol content, the low-density lipoprotein cholesterol content and the glutamic-pyruvic transaminase activity, and obviously increase the brown adipose tissue coefficient, the liver coefficient and the glucose tolerance.
Therefore, the invention provides the application of cordyceps guangdongensis fruiting body polysaccharide in preparing medicines for treating and improving obesity and related diseases.
Preferably, the cordyceps guangdongensis sporocarp polysaccharide is prepared by crushing cordyceps guangdongensis sporocarp, degreasing with petroleum ether to be colorless, volatilizing the petroleum ether, adding water for extraction, centrifuging, collecting supernate, precipitating with an ethanol water solution, collecting precipitate, and dehydrating and drying with absolute ethanol to obtain the cordyceps guangdongensis sporocarp polysaccharide.
Preferably, the ethanol water solution is ethanol water solution with the volume fraction of 95%.
Preferably, the treatment and amelioration of obesity and related diseases is the treatment and amelioration of glucose intolerance, hyperlipidemia, and fatty liver.
Preferably, the treatment and improvement of obesity and related disorders is reduction of body weight and adipose tissue weight and reduction of epididymal adipocytes.
Preferably, the treatment and amelioration of obesity and related diseases is a reduction of serum triglyceride, total cholesterol and low density lipoprotein cholesterol levels.
Preferably, the agent for treating and ameliorating obesity and related diseases is reducing fat accumulation in the liver and protecting liver tissue.
The second object of the present invention is to provide a drug for treating and improving obesity and related diseases, which contains fruiting body polysaccharides of Cordyceps guangdongensis as an active ingredient.
Preferably, the cordyceps guangdongensis fruiting body polysaccharide is prepared by crushing cordyceps guangdongensis fruiting bodies, degreasing with petroleum ether to be colorless, volatilizing the petroleum ether, adding water for extraction, centrifuging to collect supernatant, precipitating with ethanol water solution, collecting precipitate, and dehydrating and drying with absolute ethanol.
The invention has the following advantages:
(1) The cordyceps guangdongensis fruiting body polysaccharide used in the invention can obviously reduce the weight, the relative weight gain rate, the Lee's index, the adipose tissue coefficient and the size of epididymal fat cells of a high-fat-induced obese mouse, and shows the effect of effectively losing weight.
(2) The cordyceps guangdongensis fruiting body polysaccharide used in the invention can obviously reduce the content of glucose in blood of obese mice and improve the tolerance of the obese mice to glucose.
(3) The cordyceps guangdongensis fruiting body polysaccharide used in the invention can obviously reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum, thereby achieving the purpose of reducing blood fat.
(4) The cordyceps guangdongensis fruiting body polysaccharide used in the invention can obviously improve the liver coefficient, reduce the fat accumulation in the liver and the activity of glutamic-pyruvic transaminase in serum, reduce the vacuolization lesion in the liver and further play a role in protecting the liver.
Therefore, the invention provides the application of cordyceps guangdongensis fruiting body polysaccharide in preparing medicines for treating and improving obesity and related diseases. The cordyceps guangdongensis fruiting body polysaccharide plays a positive role in relieving obesity, reducing blood fat and protecting liver, shows good development and application prospects, and greatly expands the application field of cordyceps guangdongensis fruiting body polysaccharide.
Drawings
FIG. 1 shows the effect of polysaccharide from Cordyceps guangdongensis on the glucose tolerance of mice. Control group: normal diet group; high fat group: a group of high fat diets; polysaccharide group: high fat diet + cordycepin fruiting body polysaccharide group; lower case, very significant difference (P < 0.01).
FIG. 2 shows the effect of Cordyceps guangdongensis fruiting body polysaccharide on mouse body weight (A), body weight gain (B), body weight growth rate (C) and Lee' coefficient (D). Control group: normal diet group; high fat group: a group of high fat diets; polysaccharide group: high fat diet + cordycepin fruiting body polysaccharide group; ns, no significant difference; * Significant difference (P < 0.05); * Very significant differences (P < 0.01).
FIG. 3 shows the effect of Cordyceps guangdongensis fruiting body polysaccharide on the weight and shape (D) of mouse epididymis adipose tissue (A), inguinal adipose tissue (B) and brown adipose tissue (C). Control group: normal diet group; high fat group: a group of high fat diets; polysaccharide group: high fat diet + cordycepin fruiting body polysaccharide group; ns, no significant difference; * Significant difference (P < 0.05); * Very significant differences (P < 0.01).
FIG. 4 is a pathological section observation (x 200) of mouse epididymis adipocyte HE staining caused by Cordyceps guangdongensis sporocarp polysaccharide in the invention. Control group: normal diet group; high fat group: a group of high fat diets; polysaccharide group: high fat diet and cordycepin sporophore polysaccharide group.
FIG. 5 shows the effect of polysaccharide from fruiting body of Cordyceps guangdongensis according to the present invention on triglyceride (A), total cholesterol (B) and low density lipoprotein cholesterol (C) in mice. Control group: normal diet group; high fat group: a group of high fat diets; polysaccharide group: high fat diet + cordycepin fruiting body polysaccharide group; ns, no significant difference; * Very significant differences (P < 0.01).
FIG. 6 is the observation of the liver related index of mice affected by Cordyceps guangdongensis fruiting body polysaccharide and its pathological section. A, influence of cordyceps guangdongensis fruiting body polysaccharide on glutamic-pyruvic transaminase activity in mouse serum; b, the cordyceps guangdongensis fruiting body polysaccharide reduces the liver coefficient of the obese mice; c, observing the HE staining pathological section of the liver of the mouse (x 200) affected by cordyceps guangdongensis fruiting body polysaccharide; d, observation of mouse liver oil red staining pathological section affected by cordyceps guangdongensis fruiting body polysaccharide (x 200). Control group: normal diet group; high fat group: a group of high fat diets; polysaccharide group: high fat diet and cordycepin sporophore polysaccharide group.
Detailed Description
The present invention will be described in detail with reference to specific examples. The experimental methods used in the examples are all conventional experimental methods unless otherwise specified. Materials, reagents and the like used in the examples are commercially available unless otherwise specified.
The SPF male C57BL/6J mice are provided by Shenzhen Seibano Gene technology, inc., with license number: SCXK (Jing) 2019-0008.
Example 1
Preparing cordyceps guangdongensis fruiting body polysaccharide.
The cordyceps guangdongensis sporocarp dried in a 50-60 ℃ oven is prepared into superfine powder by an ultralow temperature pulverizer (-20-minus 15 ℃), 150g is weighed, 375mL of petroleum ether is added, degreasing is carried out at normal temperature until the mixture is colorless, and the petroleum ether is volatilized in a fume hood. Then, 1.5L of distilled water is added, and the mixture is placed in a water bath kettle at the temperature of 90 ℃ for leaching for 2 hours, and the mixture is stirred once every 30 min; centrifuging at 5500rpm at 4 deg.C for 15min, collecting supernatant, and repeating the extraction for 1 time. Mixing the two supernatants, concentrating to 1L in a rotary evaporator, adding 3L 95% ethanol, precipitating at 4 deg.C for 169h, centrifuging at 5500rpm for 15min, discarding the supernatant, collecting the precipitate, and dehydrating with anhydrous ethanol for 2 times. And then, drying the precipitate in an oven at 60 ℃ to obtain the cordyceps guangdongensis fruiting body polysaccharide.
Example 2
Grouping mice, modeling and dosing, and specifically comprises the following steps:
1. grouping mice: the experimental animals are SPF male C57BL/6J mice, the age of 7 weeks is 19-21g, the total weight of the experimental animals is 90, the experimental animals are only bred in the centers of microbiological institutes of Guangdong province academy of sciences, the environmental temperature is 21 +/-2 ℃, the humidity is 55 +/-10%, and the light and the dark are alternated for 12 hours. After 1 week acclimation, mice were randomly divided into 3 treatments (control group, high fat group and polysaccharide group), each treatment had 3 groups of 10 mice each.
2. Molding and administration: the control group mice were fed with conventional feed (Jiangsu province, cooperative medical biotechnology, llc), the high-fat group and the polysaccharide group mice were fed with 60% fat high-fat feed D12492 (mass ratio: casein 200, l-cystine 3, sucrose 68.8, maltodextrin 12.5, cellulose 50, soybean oil 25, lard 245, mineral 10, vitamin 10, choline tartrate 2, potassium citrate monohydrate 16.5, calcium carbonate 5.5, calcium hydrogen phosphate dihydrate 13, energy ratio: protein 20, carbohydrate 20, fat 60; purchased from Erzhou mice, two biotech Limited). After 8 weeks of feeding, the control group and the high fat group mice were gavaged with 0.8% normal saline (100. Mu.L/d), the polysaccharide group mice were gavaged with 400mg/kg/d of Cordyceps guangdongensis fruiting body polysaccharide solution, and the mice were allowed to eat and drink water freely during the experiment, and the weight and food intake of the mice were recorded weekly. By gavage to 14 weeks, the body weights of the mice of the control group, the high fat group and the polysaccharide group were significantly different.
Example 3
Measuring relevant indexes such as weight reduction and observing pathological liver sections.
1. Influence of cordyceps guangdongensis fruiting body polysaccharide on mouse glucose tolerance:
two weeks before collecting the samples, the mice eat food for 12h, the tail tips are cut off by a sterilized surgical scissors for 0.2mm to 0.3mm, blood is taken from the wound, and the fasting blood glucose value (0 min) is tested by a glucometer. Intragastric glucose solution (1 g/kg body weight) was tested for blood glucose levels at 15min, 30min, 60min, 90min and 120min, respectively. Specific data are shown in table 1.
TABLE 1 Cordyceps guangdongensis fruiting body polysaccharide for improving glucose tolerance of obese mice
Note: a, b, c, very significant difference (P < 0.01).
The results are shown in fig. 1 and table 1, after the cordyceps guangdongensis fruiting body polysaccharide is intervened for 12 weeks, compared with the control phase mice, the glucose concentration in the blood of the high-fat group and the polysaccharide group is obviously increased in 15min, 30min, 60min and 90min, while the glucose concentration in the blood of the polysaccharide group is obviously reduced compared with the high-fat group, which indicates that the cordyceps guangdongensis fruiting body polysaccharide can effectively improve the glucose tolerance of the obese mice.
2. Influence of cordyceps guangdongensis fruiting body polysaccharide on body weight and related indexes of obese mice:
the gavage 14-week mice were fasted for 24h, the body weight was measured, the body length (distance from the tip of the nose to the anus) was measured, and the weight gain (final weight-adaptation to 1-week body weight), the weight gain rate = (final weight-adaptation to 1-week body weight)/adaptation to 1-week body weight, the Lee's index = (body weight) were calculated 1/3 X 10/body length. The specific data are shown in Table 2.
TABLE 2 reduction of body weight and related index of Cordyceps guangdongensis fruiting body polysaccharide in obese mice
Note: a, B, C, significance difference (P < 0.01); a, b, c, very significant difference (P < 0.01).
As shown in fig. 2 and table 2, after 14 weeks of cordyceps guangdongensis fruiting body polysaccharide intervention, compared with the control group mice, the weight (fig. 2A), weight gain (fig. 2B), weight gain rate (fig. 2C) and Lee's index (fig. 2D) of the high fat group mice were significantly increased, while the weight, weight gain rate and Lee's index of the polysaccharide group mice were not significantly different, and the weight gain of the polysaccharide group mice and the weight gain of the high fat group mice were significantly different, indicating that cordyceps guangdongensis fruiting body polysaccharide can relieve the weight gain of C57BL/6J mice induced by high fat diet.
3. Effect of cordyceps guangdongensis ethanol extract on adipose tissue of obese mice:
mice after gastric administration for 14 weeks were fasted for 24h with CO 2 After anesthesia, cervical dislocation was sacrificed, brown fat, inguinal fat and epididymal adipose tissue were taken, the weight was recorded and adipose tissue correlation coefficient (%) = adipose tissue weight/mouse body weight was calculated. Specific data are shown in table 3.
TABLE 3 reduction of adipose tissue-related indices of Cordyceps guangdongensis fruiting body polysaccharides in obese mice
Note: a, B, C, significance difference (P < 0.01); a, b, c, very significant difference (P < 0.01).
According to the table 3 and the attached figure 3, it is found that after the cordyceps guangdongensis sporocarp polysaccharide is intervened for 14 weeks, the epididymis fat coefficient and inguinal fat coefficient of the high-fat group mouse are obviously increased, while only the inguinal fat coefficient of the polysaccharide group mouse is obviously increased, and the epididymis fat coefficient and the inguinal fat coefficient are obviously lower than those of the high-fat group mouse (fig. 3A and B); in addition, the brown fat coefficients of the mice in the high-fat group and the polysaccharide group were significantly lower than those of the control group, and the coefficients of the mice in the polysaccharide group were significantly different between the control group and the mice in the high-fat group (fig. 3C). From the adipose tissue morphology (fig. 3D), the cordyceps guangdongensis sporophore polysaccharide decreased the length and width of epididymal fat and inguinal fat in obese mice. The results show that the cordyceps guangdongensis fruiting body polysaccharide can effectively reduce the excessive fat in the high-fat-induced obese mice.
4. Observation of pathological section of Guangdong cordyceps fruiting body polysaccharide affecting epididymis fat cell HE staining of obese mice:
fixing the cut epididymis adipose tissues in 10% paraformaldehyde solution, dehydrating by adopting 80%, 90%, 95% and 100% ethanol in sequence, carrying out xylene transparent treatment, then carrying out paraffin embedding and slicing; the slices are decolorized in xylene for 20min, absolute ethyl alcohol for 5min, 75% ethyl alcohol for 5min and tap water in sequence, and then placed in hematoxylin for dyeing for 3-5 min; staining with eosin for 5min, sequentially decolorizing with anhydrous ethanol for 5min and xylene for 5min, and sealing with neutral gum. The changes in epididymal adipocytes were observed by electron microscopy (Leica, DM6/DMC 4500).
According to the attached figure 4, after the cordyceps guangdongensis sporocarp polysaccharide is intervened for 14 weeks, compared with the control group of mice, the epididymal fat cells of the high-fat group of mice are obviously increased in diameter, and the number of the fat cells in the same visual field range is obviously reduced. Compared with the mice in the high fat group, the diameter of the epididymal fat cells of the mice in the polysaccharide group is obviously reduced, and the number of the fat cells in the same visual field range is obviously increased. The results show that the cordyceps guangdongensis sporophore polysaccharide can obviously reduce the diameter of epididymal fat cells.
5. The influence of cordyceps guangdongensis fruiting body polysaccharide on relevant indexes of blood fat in mouse serum:
the gavage 14 week mice were fasted for 24h and placed in a closed cage with CO 2 Anaesthetizing, taking blood from abdominal cavity, standing at room temperature for 1h, centrifuging at 3000rpm for 15min, and collecting upper layer serum. The change of the blood lipid index in the serum is measured by using a kit (purchased from Nanjing institute of bioengineering), and the specific data are shown in Table 4.
TABLE 4 influence of Cordyceps guangdongensis fruiting body polysaccharide on mouse serum index
Note: a, b, c, very significant difference (P < 0.01).
As can be seen from table 4 and fig. 5, after 14 weeks of intervention of cordyceps guangdongensis fruiting body polysaccharides, compared with control mice, the contents of triglyceride (fig. 5A), total cholesterol (fig. 5B) and low-density lipoprotein cholesterol (fig. 5C) in the serum of the high-fat group mice are significantly increased, while the contents of triglyceride and low-density lipoprotein cholesterol in the serum of the polysaccharide group mice are not significantly different, and 3 blood lipid indexes in the serum of the polysaccharide group mice are significantly lower than those of the high-fat group mice. The results show that the cordyceps guangdongensis fruiting body polysaccharide can effectively reduce related indexes of hyperlipidemia in serum of obese mice induced by high-fat diet.
6. The Cordyceps guangdongensis fruiting body polysaccharide influences mouse liver related indexes and pathological section observation thereof:
the gavage 14-week mice were fasted for 24h with CO 2 Anaesthetizing, taking blood from the abdominal cavity, dislocation and killing the cervical vertebra, taking liver tissues, weighing, and calculating the liver correlation coefficient (%) = the weight of the liver tissues/the weight of the mouse. The liver was cut into two portions, and one portion was soaked in 4% paraformaldehyde tissue fixative. Slicing the liver tissue, and observing an HE stained section in the synchronous step 4; simultaneously, carrying out oil red infection for 8-10 min (keeping out of the sun), taking out the slices, staying for 3s, immersing in 60% isopropanol for differentiation for 2 times, wherein the time is 3s and 5s, and then sequentially immersing in pure water for immersion and washing for 2 times, each for 10s; hematoxylin staining is carried out for 3-5min, 60% ethanol is differentiated for 2-8 s, distilled water is washed for 10s, bluing liquid is bluing for 1s, tap water is used for immersion washing for 10-15 s, and finally, glycerol gelatin is used for sealing tablets and sealing tablets. Changes in lipid droplets in the liver were observed by electron microscopy (Leica, DM6/DMC 4500).
Referring to fig. 6A, the serum glutamic-pyruvic transaminase activity (related to the degree of liver cell destruction) of the control group and the polysaccharide group of mice was significantly reduced compared to the high-fat group of mice, without significant difference therebetween. The liver coefficients of the control group mice were significantly higher than those of the high-fat and polysaccharide groups, and the liver coefficients of the polysaccharide group mice were significantly higher than those of the high-fat group mice (fig. 6B). The observation result of an HE (human hematopoietic) staining microscope shows that (the cell nucleus is blue, the cytoplasm is red), lipid vacuole pathological changes with different sizes appear in liver cells of mice in a high-fat group, the area of the total lipid vacuole is large, and the cell boundary and the cell shape are fuzzy; while the liver cell boundaries and morphology were clear and regular with fewer lipid vacuolar lesions in the control and control mice (fig. 6C). The observation result of an oil red staining microscope shows that compared with the control group of mice, the livers of the mice in the high fat group obviously contain more orange fat drops, and more expanded bubbles exist among cells; the livers of the polysaccharose mice are very light orange red, and the cells have fewer expanded air bubbles. The results show that the cordyceps guangdongensis fruiting body polysaccharide can effectively weaken the damage degree of liver cells and relieve the accumulation of lipid (such as lipid droplets) in the liver.
In conclusion, the invention aims to research the influence of cordyceps guangdongensis fruiting body polysaccharide on high fat induced obese mouse glucose tolerance, body weight gain rate, adipose tissue weight, serum blood lipid index and liver tissue, and finally proves that the intervention of cordyceps guangdongensis fruiting body polysaccharide can obviously reduce body weight, body weight gain rate, lee's index, epididymis fat and inguinal fat coefficient, triglyceride content, total cholesterol content, low density lipoprotein cholesterol content and glutamic-pyruvic transaminase activity, and obviously increase brown adipose tissue coefficient, liver coefficient and glucose tolerance.
Therefore, the cordyceps guangdongensis fruiting body polysaccharide plays a positive role in relieving obesity, reducing blood fat and protecting the liver. The invention provides application of cordyceps guangdongensis fruiting body polysaccharide in weight reduction, lipid reduction and liver protection, and provides a new resource for development of related products in the fields of biomedicine and health care products.
The above list is only a few embodiments of the present invention. However, the present invention is not limited to the above embodiments, and there are many variations. All modifications which can be derived or suggested by a person skilled in the art from the disclosure of the invention should be considered as within the scope of the invention.
Claims (4)
1. The application of cordyceps guangdongensis fruiting body polysaccharide in preparing a medicine for treating and improving obesity and related diseases, wherein the treatment and improvement of obesity and related diseases is the treatment and improvement of glucose intolerance, hyperlipidemia and fatty liver and weight reduction;
the cordyceps guangdongensis sporophore polysaccharide is prepared by crushing cordyceps guangdongensis sporophore at ultralow temperature, degreasing with petroleum ether to colorless, volatilizing the petroleum ether, adding water for extraction, centrifuging to collect supernatant, precipitating with ethanol water solution, collecting precipitate, and dehydrating and drying with anhydrous ethanol.
2. The use according to claim 1, wherein the aqueous ethanol solution is 95% by volume aqueous ethanol solution.
3. The use according to claim 1, wherein the treatment or amelioration of obesity and related disorders is a reduction of serum triglyceride, total cholesterol and low density lipoprotein cholesterol levels.
4. The use according to claim 1, wherein the medicament for the treatment and amelioration of obesity and related diseases is the reduction of fat accumulation in the liver and the protection of liver tissue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210231757.6A CN114432337B (en) | 2022-03-10 | 2022-03-10 | Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210231757.6A CN114432337B (en) | 2022-03-10 | 2022-03-10 | Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114432337A CN114432337A (en) | 2022-05-06 |
| CN114432337B true CN114432337B (en) | 2022-10-18 |
Family
ID=81359668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210231757.6A Active CN114432337B (en) | 2022-03-10 | 2022-03-10 | Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114432337B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531478B (en) * | 2022-10-28 | 2024-02-02 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Cordyceps guangdong hypoglycemic pharmaceutical composition for treating type 2 diabetes and related complications and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109021132B (en) * | 2018-07-23 | 2021-01-29 | 广东省微生物研究所（广东省微生物分析检测中心） | Cordyceps guangdongensis polysaccharide CCG-PSW and CCG-PSS as well as preparation method and application thereof |
| CN109053923B (en) * | 2018-07-23 | 2021-05-25 | 广东省微生物研究所（广东省微生物分析检测中心） | Cordyceps guangdongensis polysaccharide CCG-CPS and preparation method and application thereof |
| CN113546097B (en) * | 2021-07-21 | 2022-07-01 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia |
-
2022
- 2022-03-10 CN CN202210231757.6A patent/CN114432337B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114432337A (en) | 2022-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6316002B1 (en) | Germination activated red Ganoderma lucidum spores and method for producing the same | |
| CN113546097B (en) | Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia | |
| CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
| CN102697035A (en) | Cordyceps anti-aging pellet | |
| CN114632101B (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound and preparation method and application thereof | |
| CN103190621A (en) | Propolis soft capsule and preparation method thereof | |
| Wu et al. | Hypoglycemic effect of okra aqueous extract on streptozotocin-induced diabetic rats | |
| CN106551398A (en) | A kind of anti-aging cream taste and preparation method thereof | |
| CN114432337B (en) | Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases | |
| CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
| CN115887485A (en) | Application of pachyman in regulating intestinal microbial structure and metabolite of obese organism | |
| CN105663000A (en) | Rhizome bletillae moisturizing gel product and preparation method thereof | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN101884783A (en) | Wheat bran polypeptide-containing anti-fatigue traditional Chinese medicine and preparation method thereof | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN104940241B (en) | A kind of selenium worm grass compound preparation of prevention climacteric metancholia of women | |
| CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
| CN104382985A (en) | Pharmaceutical composition for preventing and treating non-alcoholic fatty liver disease | |
| CN103100028A (en) | Soft capsule favorable for reducing alcoholic liver injury and preparation method thereof | |
| CN110680840B (en) | Application of small blackberry extract in preparation of hypolipidemic drugs | |
| CN103933146A (en) | Pollen product capable of adjusting human body immunity | |
| CN108210745A (en) | One kind has immunoregulatory auxiliary hyperglycemic compound capsules and preparation method thereof | |
| CN106937923A (en) | Lucid ganoderma-pollen skin care health care frost | |
| CN105535866A (en) | Medicine for treating hyperlipidemia and preparation method thereof | |
| CN108653316A (en) | Tremella polysaccharides are preparing the application in preventing antiobesity agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |